The Development of Tinnitus in Patients With SSNHL: Insights From fMRI and Metabolomics
NCT ID: NCT06355102
Last Updated: 2024-10-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
90 participants
OBSERVATIONAL
2024-04-15
2026-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* What are the peripheral and central influencing factors that contribute to tinnitus in patients with SSNHL?
* Can serum metabolic biomarkers be identified to predict and monitor tinnitus prognosis in these patients?
Participants in this study will include patients with SSNHL and tinnitus, patients with SSNHL without tinnitus, and healthy subjects. They will be asked to undergo a series of assessments, including audiological tests, vestibular function examinations, and functional magnetic resonance imaging (fMRI). Additionally, blood samples will be collected for metabolomics analysis.
Investigators will compare the brain functional states and serum metabolite profiles of patients with SSNHL and tinnitus to those without tinnitus. Morever, tinnitus symptom characteristics, audiological outcomes, and brain functional states will be assessed during time.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Resting-State Neural Connectivity in Patients With Subjective Tinnitus Without Bother
NCT01049828
Brain Imaging of Tinnitus
NCT00359931
Brain Mechanism and Outcome of Surgical Intervention of Conductive Hearing Loss.
NCT06535282
Investigation to the Mechanism of the Neuroplastic Modulation in Central Auditory Tract
NCT05591807
Tinnitus in Patients With and Without Sensorineural Hearing Loss
NCT04162405
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study aims to enroll 30 patients with SSNHL accompanied by tinnitus, 30 patients with SSNHL without tinnitus, and 30 healthy subjects. Investigators will record general demographic information, tinnitus symptom characteristics, audiological examinations, vestibular function tests, and other information for each group during the acute phase of SSNHL onset. Using functional magnetic resonance imaging (fMRI), investigators will compare the brain functional states of patients with SSNHL accompanied by tinnitus and those without tinnitus during the acute phase to investigate the peripheral influencing factors and central mechanisms of tinnitus production. Additionally, investigators will conduct metabolomics analysis to compare the serum metabolite profiles of these two patient groups to identify serum metabolic biomarkers and prognostic biomarkers for tinnitus in patients with SSNHL accompanied by tinnitus. Furthermore, this study will conduct follow-up assessments on the subjects at 1 month, 3 months, and 6 months after the onset of SSNHL, reviewing changes in their symptom characteristics, audiological examinations, and fMRI. At 6 months after the onset, patients will be divided into a tinnitus recovery group and a tinnitus non-recovery group based on their tinnitus recovery status. Investigators will compare the general demographic characteristics, audiological examinations, and brain functional MRI findings between the two groups to explore the role and mechanisms of brain plasticity changes in the recovery or chronicity of tinnitus in patients with SSNHL.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SSNHL with Tinnitus
Patients diagnosed with sudden sensorineural hearing loss accompanied with acute occuring tinnitus symptoms.
Conventional treatment and care
Conventional treatment and care
SSNHL without Tinnitus
Patients diagnosed with sudden sensorineural hearing loss without acute occuring tinnitus symptoms.
Conventional treatment and care
Conventional treatment and care
Health Control
Healthy subjects with normal hearing and no tinnitus.
Conventional treatment and care
Conventional treatment and care
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Conventional treatment and care
Conventional treatment and care
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Age between 18 and 65 years old;
2. Meets the diagnostic criteria for SSNHL; untreated within 5 days after onset;
3. Presence of tinnitus;
4. Able to complete questionnaires independently and cooperate with fMRI and follow-up assessments.
2. Group of SSNHL without Tinnitus:
1. Age between 18 and 65 years old;
2. Meets the diagnostic criteria for SSNHL; untreated within 5 days after onset;
3. Absence of tinnitus;
4. Able to complete questionnaires independently and cooperate with fMRI and follow-up assessments.
3. Healthy Control:
1. Age between 18 and 65 years old;
2. Normal hearing screening results;
3. Able to complete questionnaires independently and cooperate with fMRI and follow-up assessments.
Exclusion Criteria
2. Presence of brain organic diseases such as cerebral infarction, brain tumor, or contraindications for functional magnetic resonance imaging (fMRI) during nuclear magnetic resonance (NMR) examination;
3. History of mental illness, including anxiety, depression, insomnia, etc.;
4. Individuals unable to cooperate due to severe mental factors.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The First Affiliated Hospital with Nanjing Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Liyuan Zhang, M.D.
Role: PRINCIPAL_INVESTIGATOR
Department of Otolaryngology, the First Affiliated Hospital, Nanjing Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Otolaryngology, the First Affiliated Hospital, Nanjing Medical University
Nanjing, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-SR-116
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.